Merck KGaA Collaborates with Iktos to Deploy AI in New Drug Design
Shots:
- Iktos will leverage its de novo generative design technology to be used in a structure-enabled context- facilitating the rapid & cost-effective design of Merck KGaA’s drug discovery program
- The collaboration follows the previous agreement of the companies signed in 2019. Merck KGaA is utilizing Iktos’ de novo design software platform Makya for MPO
- Iktos’ AI technology is based on deep generative models that help bring speed & efficiency to the drug discovery process by automatically designing virtual novel molecules having desired activities for treating a disease
Ref: Businesswire | Image: Merck KGaA
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com